Medical Prognosis Institute A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medical Prognosis Institute A/S
ViroMed looks to bluebird to take its humanized antibody to the next steps of development in immuno-oncology. Takeda gets option for Cour's nanoparticle technology in Celiac disease, as well as up to three other indications.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing